Viemed (VMD) Insider Filing: RSU Grants and Phantom Units Reported
Rhea-AI Filing Summary
Sabrina Heltz, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and changes in beneficial ownership in August 2025. The Form 4 shows grants and vesting events: on 08/19/2025 she was granted 15,029 restricted stock units (RSUs) that vest on 08/19/2026 and 3,757 phantom share units that vest on 08/19/2026. On 08/20/2025 a previously awarded 15,732 RSUs vested and were acquired, and after the reported transactions she beneficially owned 67,491 common shares. Phantom shares pay cash based on the issuer's share price at vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Director received equity-based compensation (15,029 RSUs) which aligns incentives with shareholders
- Vested RSUs converted into shares (15,732 acquired on 08/20/2025), increasing reported beneficial ownership to 67,491 common shares
Negative
- None.
Insights
TL;DR: Director compensation was paid largely in equity and deferred cash units, reflecting routine governance-aligned incentives.
The filing documents director-level compensation delivered as restricted stock units and phantom share units with one tranche vesting immediately (08/20/2025) and other awards vesting on the one-year anniversaries (08/19/2026 and 08/19/2026). Equity-based pay aligns the director's interests with shareholders while phantom units preserve cash flexibility until settlement. The report is a standard Section 16 disclosure of grants and vesting; there are no sales or external-party transfers reported.
TL;DR: Transaction is routine insider compensation with limited immediate market impact.
The Form 4 shows acquisition of vested RSUs (15,732 shares) and newly granted awards (15,029 RSUs and 3,757 phantom units). After these events the director beneficially owns 67,491 shares. These are standard non-derivative and derivative compensation instruments; there is no cash sale or disposition reported that would suggest near-term selling pressure. The phantom units convert to cash value at vesting, not shares, which limits immediate share dilution from that component.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 15,732 | $0.00 | $0.00 |
| Exercise | Common Shares | 15,732 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 15,029 | $0.00 | $0.00 |
| Grant/Award | Phantom Share Units | 3,757 | $0.00 | $0.00 |
Footnotes (5)
- F1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.
- F2. On August 20, 2024, the reporting person was granted Restricted Stock Units which vest on August 20, 2025.
- F3. Restricted Stock Units (RSUs) granted to reporting person on August 19, 2025, which vest on the first anniversary of the grant date.
- F4. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.
- F5. Represents an award granted on August 19, 2025 under the Issuer's Phantom Share Plan which vests on the first anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.